CD4 and relapsing-remitting multiple sclerosis: In this study, we chose evaluate the feasibility of blocking CD4+ T cell emigration from lymph nodes because FTY720, also known as fingolimod or Gilenya®, is already an FDA-approved treatment for relapsing-remitting multiple sclerosis and chronic inflammatory demyelinating polyneuropathy that has been well-characterized (Fig. 5)49,50.